Tarsus Pharmaceuticals, Inc. (TARS) Stock Price & Analysis
Tarsus Pharmaceuticals, Inc. (TARS) rose 0.00% to USD 58.66 as of July 25, 2026 at 03:10 UTC, according to Nexqual real-time market data.
TARS last closed at USD 58.66; the session ranged USD 57.54–59.06 on volume of 446,493 shares. Market capitalization is —, with a 52-week range of USD 38.51–85.25 (NMS). Source: Nexqual, July 25, 2026 at 03:10 UTC.
Key Statistics (as of July 25, 2026 at 03:10 UTC)
| Price | USD 58.66 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 58.66 |
| Open | USD 58.66 |
| Day Range | USD 57.54 – 59.06 |
| 52-Week Range | USD 38.51 – 85.25 |
| Volume | 446,493 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (TARS)
Nexqual's technical model rates TARS "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:10 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 47.48 (neutral) |
| vs SMA50 | Below (USD 61.57) |
| MACD | -1.39 (negative) |
From Tarsus Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Our Approach: TP-04 Topical Formulation for Ocular Rosacea There are no FDA-approved therapeutics for ocular rosacea available today.
- Intellectual Property We protect our intellectual property rights and proprietary technology with a combination of patent rights that we own or license in certain fields of use, trademark rights, confidentiality procedures and contractual provisions.
- We seek not only to protect our intellectual property rights and proprietary technology in select key global markets, but also to supplement our intellectual property portfolio with new filings and applications to enhance such protection and support commercialization of current and future product candidates.
- Our continuing research and development activities, technical expertise and contractual arrangements supplement our existing intellectual property protection and help us maintain our competitive position, and we rely on trade secrets to protect our proprietary information and technologies, especially where we do not believe patent protection is appropriate or obtainable, or where such patents would be difficult to enforce.
Partnerships
- In March 2024, we executed an agreement with GrandPharma and LianBio to transition these rights to GrandPharma.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PHAT | Phathom Pharmaceuticals, Inc. | USD 11.44 | ▼ 2.22% |
| STOK | Stoke Therapeutics, Inc. | USD 29.3 | ▲ 1.17% |
| EWTX | Edgewise Therapeutics, Inc. | USD 40.84 | ▲ 6.55% |
| FDMT | 4D Molecular Therapeutics, Inc. | USD 10.07 | ▼ 8.12% |
| PRAX | Praxis Precision Medicines, Inc | USD 325.3 | ▲ 4.23% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:10 UTC. This page is informational and not investment advice.